{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:56Z","timestamp":1794047516047,"version":"4.8.0"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard-of-care therapy with frontline DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, rituximab). However, treatment strategies following relapse after DA-EPOCH-R are not well defined. We, therefore, performed a retrospective review of PMBCL patients with relapsed\/refractory (R\/R) disease after frontline DA-EPOCH-R to obtain better insight into outcomes with salvage therapy and autologous stem cell transplant (SCT). Our cohort consisted of 107 patients with R\/R PMBCL. Ninety patients qualified for the intention-to-treat salvage therapy analysis. With a median follow up of 48.9 months in the salvage therapy analysis, the median progression-free survival was 5.4 months (95% confidence interval [95% CI]: 2.3 months-not reached) with a 5-year overall survival rate of 78% (95% CI: 69-88). Compared to relapsed patients (relapsing &gt;6 months after frontline DA-EPOCH-R, N=23), refractory patients (relapsing &lt;6 months after frontline DA-EPOCH-R, N=67) had an inferior overall response rate (48% vs. 83%), complete remission rate (19% vs. 44%), and 2-year progression-free survival rate (30% vs. 69%) with initial salvage therapy. Forty-eight patients (53%) underwent autologous SCT after salvage therapy with estimated 5-year progression-free and overall survival rates of 85% (95% CI: 75-96) and 88% (95% CI: 79-99), respectively. There were no relapses among 29 patients in complete remission prior to autologous SCT. In conclusion, this analysis is the largest review of R\/R PMBCL to date and demonstrates unfavorable outcomes for patients with refractory disease after frontline DA-EPOCH-R chemotherapy. Patients able to undergo autologous SCT, especially those in complete remission prior to the transplant, had excellent outcomes.<\/jats:p>","DOI":"10.3324\/haematol.2025.288232","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:08:56Z","timestamp":1761811736000},"page":"1389-1395","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R"],"prefix":"10.3324","volume":"111","author":[{"given":"Brian","family":"Hess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mckenzie","family":"Sorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Escribano-Serrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelly","family":"De Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor R.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayo S.","family":"Falade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Merryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Nachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"88068","doi-asserted-by":"crossref","unstructured":"[No authors listed]. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997; 89(11):3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"88069","doi-asserted-by":"crossref","unstructured":"Dunleavy K, Pittaluga S, Maeda LS. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368(15):1408-1416.","DOI":"10.1056\/NEJMoa1214561"},{"key":"88070","doi-asserted-by":"crossref","unstructured":"Martelli M, Ceriani L, Zucca E. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014; 32(17):1769-1775.","DOI":"10.1200\/JCO.2013.51.7524"},{"key":"88071","doi-asserted-by":"crossref","unstructured":"Sehn LH, Antin JH, Shulman LN. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998; 91(2):717-723.","DOI":"10.1182\/blood.V91.2.717.717_717_723"},{"key":"88072","doi-asserted-by":"crossref","unstructured":"Giulino-Roth L, O\u2019Donohue T, Chen Z. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017; 179(5):739-747.","DOI":"10.1111\/bjh.14951"},{"key":"88073","doi-asserted-by":"crossref","unstructured":"Vardhana S, Hamlin PA, Yang J. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018; 24(10):2133-2138.","DOI":"10.1016\/j.bbmt.2018.06.009"},{"key":"88074","doi-asserted-by":"crossref","unstructured":"Soueidy C, Kourie HR. Updates in the management of primary mediastinal B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2023; 23(12):866-873.","DOI":"10.1016\/j.clml.2023.08.014"},{"key":"88075","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Santoro A, Gritti G. Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol. 2019; 37(33):3081-3089.","DOI":"10.1200\/JCO.19.01492"},{"key":"88076","doi-asserted-by":"crossref","unstructured":"Armand P, Rodig S, Melnichenko V. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019; 37(34):3291-3299.","DOI":"10.1200\/JCO.19.01389"},{"key":"88077","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7):640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"88078","doi-asserted-by":"crossref","unstructured":"Kamdar M, Solomon SR, Arnason J. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022; 399(10343):2294-2308.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"88079","doi-asserted-by":"crossref","unstructured":"Crombie JL, Nastoupil LJ, Redd R. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021; 5(18):3563-3567.","DOI":"10.1182\/bloodadvances.2021004880"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12964\/79021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12964\/79873","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12964\/79021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:08Z","timestamp":1794046208000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.288232","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}